ClinicalTrials.gg

Program

enlicitide decanoate

Also written as “Enlicitide Decanoate”, “Enlicitide decanoate” and “Enclitide Chloride”.

Its studies are mostly in Hypercholesterolemia · Hyperlipoproteinemia Type II · Arteriosclerosis, led by Merck.

Furthest: phase 3, since Jul 10, 202315 company-led studies, 4 open or runningNext primary completion: Nov 26, 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Merck154 open or runningphase 3since Jul 10, 2023Feb 22, 2022Nov 26, 2027phase 3 · NCT07821944

Also a collaborator on its studies: celerion.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Feb 22, 2022First study: phase 2 study in HypercholesterolemiaFirst studyNCT05261126 · 381 enrolled · United States, Germany, Japan and more
  2. Jun 5, 2023Phase 1 study in HypercholesterolemiaNCT05934292 · 33 enrolled · United States
  3. Jul 10, 20232 phase 3 studies in HypercholesterolemiaNCT05952869, NCT05952856
  4. Aug 17, 2023Phase 3 study in ArteriosclerosisNCT06008756 · 14,550 enrolled · United States, Argentina, Australia and more
  5. Jul 1, 2024Phase 3 study in HypercholesterolemiaNCT06492291 · 3,000 enrolled · United States, Argentina, Australia and more
  6. Sep 9, 2024Phase 1 study in HypercholesterolemiaNCT06592339 · 24 enrolled · United States
  7. Oct 1, 20242 phase 1 studies in HealthyNCT06625814, NCT06658652
  8. Nov 13, 20243 phase 1 studies in HealthyNCT06691906, NCT06699355, NCT06699329
  9. Jan 9, 2025Phase 1 study in HealthyNCT06772792 · 36 enrolled · United States
  10. Jul 1, 2025Phase 3 study in Heterozygous Familial Hypercholesterolemia (HeFH)NCT07058077 · 153 planned · United States, Australia, Belgium and more
  11. Sep 9, 2026Phase 3 study in HyperlipidemiasNCT07821944 · 150 planned · India

Ahead

  1. Nov 26, 2027Primary completion: phase 3 study in HyperlipidemiasNCT07821944
  2. Oct 13, 2028Primary completion: phase 3 study in HypercholesterolemiaNCT06492291
  3. Nov 29, 2029Primary completion: phase 3 study in ArteriosclerosisNCT06008756
  4. Dec 4, 2033Primary completion: phase 3 study in Heterozygous Familial Hypercholesterolemia (HeFH)NCT07058077

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 15 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07821944Hyperlipidemias · India3RecruitingNov 26, 2027150
NCT07058077Heterozygous Familial Hypercholesterolemia (HeFH) · United States, Australia, Belgium and more3RecruitingDec 4, 2033153
NCT06772792Healthy · United States1CompletedJun 21, 202436
NCT06699355Healthy · United States1CompletedDec 29, 202318
NCT06699329Healthy · United States1CompletedMay 24, 202438
NCT06691906Healthy · United States1CompletedMay 1, 202440
NCT06658652Healthy · United States1CompletedDec 26, 202334
NCT06625814Healthy · United States1CompletedAug 19, 202428
NCT06592339Hypercholesterolemia · United States1CompletedDec 29, 202224
NCT06492291Hypercholesterolemia · United States, Argentina, Australia and more3Active, not recruitingOct 13, 20283,000
NCT06008756Arteriosclerosis · United States, Argentina, Australia and more3Active, not recruitingNov 29, 202914,550
NCT05952869Hypercholesterolemia · United States, Australia, Brazil and more3CompletedApr 7, 2025303
NCT05952856Hypercholesterolemia · United States, Argentina, China and more3CompletedJul 28, 20252,912
NCT05934292Hypercholesterolemia · United States1CompletedJan 19, 202433
NCT05261126Hypercholesterolemia · United States, Germany, Japan and more2CompletedNov 28, 2022381

How it is read

Names in the registry

  • “Enlicitide Decanoate”, 11 entries
  • “Enlicitide decanoate”, 2 entries
  • “Enclitide Chloride”, 1 entry
  • “MK-0616”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.